Janus Henderson Group PLC Trims Stock Position in Ardelyx, Inc. $ARDX

Posted by Stanley Muller on Aug 2nd, 2026

Janus Henderson Group PLC cut its holdings in Ardelyx, Inc. (NASDAQ:ARDX – Free Report) by 42.3% during the first quarter, HoldingsChannel reports. The fund owned 8,371,234 shares of the biopharmaceutical company’s stock after selling 6,143,458 shares during the period. Janus Henderson Group PLC’s holdings in Ardelyx were worth $50,144,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in ARDX. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Ardelyx by 2.9% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 159,061 shares of the biopharmaceutical company’s stock valued at $781,000 after purchasing an additional 4,436 shares during the period. Goldman Sachs Group Inc. lifted its stake in shares of Ardelyx by 10.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 2,378,738 shares of the biopharmaceutical company’s stock valued at $11,680,000 after purchasing an additional 221,486 shares during the last quarter. Focus Partners Wealth purchased a new position in shares of Ardelyx during the 1st quarter worth $72,000. Strs Ohio purchased a new position in shares of Ardelyx during the 1st quarter worth $135,000. Finally, Legal & General Group Plc grew its holdings in shares of Ardelyx by 13.5% during the 2nd quarter. Legal & General Group Plc now owns 275,344 shares of the biopharmaceutical company’s stock worth $1,080,000 after purchasing an additional 32,738 shares during the period. 58.92% of the stock is currently owned by hedge funds and other institutional investors.

Ardelyx Stock Down 1.8%

NASDAQ:ARDX opened at $4.95 on Friday. The company has a quick ratio of 3.28, a current ratio of 3.49 and a debt-to-equity ratio of 1.37. The stock’s fifty day moving average is $5.51 and its two-hundred day moving average is $6.15. Ardelyx, Inc. has a 52 week low of $4.07 and a 52 week high of $8.40. The stock has a market capitalization of $1.22 billion, a price-to-earnings ratio of -21.52 and a beta of 0.61.

Ardelyx (NASDAQ:ARDX – Get Free Report) last released its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.02). Ardelyx had a negative return on equity of 38.11% and a negative net margin of 13.58%.The firm had revenue of $94.47 million for the quarter, compared to analysts’ expectations of $92.78 million. During the same quarter in the prior year, the business earned ($0.17) earnings per share. The company’s quarterly revenue was up 27.5% on a year-over-year basis. Research analysts anticipate that Ardelyx, Inc. will post -0.08 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on ARDX. LADENBURG THALM/SH SH initiated coverage on shares of Ardelyx in a report on Tuesday, June 16th. They issued a “buy” rating and a $16.00 price objective on the stock. Weiss Ratings lowered shares of Ardelyx from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, June 29th. Finally, Zacks Research cut shares of Ardelyx from a “hold” rating to a “strong sell” rating in a research report on Wednesday, July 22nd. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $15.73.

Get Our Latest Analysis on Ardelyx

Insider Activity

In other Ardelyx news, insider Mike Kelliher sold 7,248 shares of Ardelyx stock in a transaction dated Thursday, May 21st. The stock was sold at an average price of $6.27, for a total value of $45,444.96. Following the completion of the transaction, the insider directly owned 357,418 shares of the company’s stock, valued at $2,241,010.86. The trade was a 1.99% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Eric Duane Foster sold 7,998 shares of the business’s stock in a transaction dated Thursday, May 21st. The stock was sold at an average price of $6.27, for a total transaction of $50,147.46. Following the sale, the insider owned 417,972 shares in the company, valued at $2,620,684.44. This trade represents a 1.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 24,572 shares of company stock worth $154,066. 5.30% of the stock is owned by corporate insiders.

About Ardelyx

(Free Report)

Ardelyx, Inc (NASDAQ: ARDX) is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing targeted small molecule drugs for cardio‐renal and gastrointestinal diseases. The company’s lead marketed product, tenapanor (sold under the brand name XPHOZAH in the United States), is approved for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis. Ardelyx’s proprietary approach targets epithelial transporters in the gastrointestinal tract, offering localized activity with limited systemic exposure.

Beyond tenapanor, Ardelyx’s development pipeline includes treatments designed to address other complications in kidney disease and related metabolic disorders.

Janus Henderson Group PLC Trims Stock Position in Ardelyx, Inc. $ARDX

Ardelyx Stock Down 1.8%

Wall Street Analyst Weigh In

Insider Activity

About Ardelyx

Recommended Stories

You might be interested in: